Literature DB >> 24703317

Type of breast cancer diagnosis, screening, and survival.

Carla Cedolini1, Serena Bertozzi2, Ambrogio P Londero3, Sergio Bernardi4, Luca Seriau2, Serena Concina2, Federico Cattin2, Andrea Risaliti2.   

Abstract

INTRODUCTION: Breast cancer screening is known to reduce mortality. In the present study, we analyzed the prevalence of breast cancers detected through screening, before and after introduction of an organized screening, and we evaluated the overall survival of these patients in comparison with women with an extrascreening imaging-detected breast cancer or those with palpable breast cancers.
MATERIALS AND METHODS: We collected data about all women who underwent a breast operation for cancer in our department between 2001 and 2008, focusing on type of tumor diagnosis, tumor characteristics, therapies administered, and patient outcome in terms of overall survival, and recurrences. Data was analyzed by R (version 2.15.2), and P < .05 was considered significant.
RESULTS: Among the 2070 cases of invasive breast cancer we considered, 157 were detected by regional mammographic screening (group A), 843 by extrascreening breast imaging (group B: 507 by mammography and 336 by ultrasound), and 1070 by extrascreening breast objective examination (group C). The 5-year overall survival in groups A, B, and C were, respectively, 99% (95% CI, 98%-100%), 98% (95% CI, 97%-99%), and 91% (95% CI, 90%-93%), with a significant difference between the first 2 groups and the third (P < .05) and a trend between groups A and B (P = .081).
CONCLUSION: The diagnosis of invasive breast cancer with screening in our population resulted in a survival gain at 5 years from the diagnosis, but a longer follow-up is necessary to confirm this data.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast cancer screening; Invasive breast cancer; Mammographic screening; Overall survival

Mesh:

Year:  2014        PMID: 24703317     DOI: 10.1016/j.clbc.2014.02.004

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  29 in total

1.  A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer.

Authors:  Zhen Yang; Syed Muhammad Usama; Feng Li; Kevin Burgess; Zheng Li
Journal:  Medchemcomm       Date:  2018-08-03       Impact factor: 3.597

2.  Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer.

Authors:  Shuo Wang; Jun Zhang; Fan-Jie Meng; Yi-Jie Yan; Bin Wang; Zhi-Yu Guan
Journal:  Oncol Lett       Date:  2020-04-03       Impact factor: 2.967

3.  Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.

Authors:  Carla Cedolini; Serena Bertozzi; Ambrogio P Londero; Luca Seriau; Michela Andretta; Diane Agakiza; Sandro Fongione; Alessandro Uzzau; Andrea Risaliti
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Integrated Analysis of Genomic and Transcriptomic Profiles Identified the Role of GTP Binding Protein-4 (GTPBP4) in Breast Cancer.

Authors:  Yiming Hu; Jiaheng Xie; Liang Chen; Qikai Tang; Wei Wei; Wenfeng Lin; Wang Du; Tinghong Xiang; Lu Yin; Jing Ji
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

5.  Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.

Authors:  Huan Gao; Yue Zhang; Lei Dong; Xiao-Yu Qu; Li-Na Tao; Yue-Ming Zhang; Jing-Hui Zhai; Yan-Qing Song
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

6.  Lockdown of Breast Cancer Screening for COVID-19: Possible Scenario.

Authors:  Gianluca Vanni; Marco Pellicciaro; Marco Materazzo; Valentina Bruno; Chiara Oldani; Chiara Adriana Pistolese; Chiara Buonomo; Jonathan Caspi; Paola Gualtieri; Agostino Chiaravalloti; Leonardo Palombi; Emilio Piccione; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

7.  Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Authors:  Zeyu Xing; Menglu Zhang; Xin Wang; Jiaqi Liu; Gang Liu; Kexin Feng; Xiang Wang
Journal:  J Mol Histol       Date:  2021-05-19       Impact factor: 2.611

8.  Factors Influencing the Onset of Neoadjuvant Therapy in Breast Cancer Patients.

Authors:  Carolin Müller; Stephanie Juhasz-Böss; Gilda Schmidt; Erich-Franz Solomayer; Ingolf Juhasz-Böss; Georg-Peter Breitbach
Journal:  Breast Care (Basel)       Date:  2019-08-29       Impact factor: 2.860

9.  Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer.

Authors:  Serena Bertozzi; Ambrogio P Londero; Carla Cedolini; Alessandro Uzzau; Luca Seriau; Sergio Bernardi; Stefano Bacchetti; Enrico Maria Pasqual; Andrea Risaliti
Journal:  Springerplus       Date:  2015-11-10

10.  miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway.

Authors:  Chuansheng Li; Jingwei Zhang; Zhongliang Ma; Fan Zhang; Wenlong Yu
Journal:  Onco Targets Ther       Date:  2018-07-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.